Author

S. Jangra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 10 Organism:mouse· 7 Organism:human· 5 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2

Frequent Co-Authors

M. Schotsaert· 11 shared A. Garcia-Sastre· 9 shared R. Rathnasinghe· 7 shared T. Kehrer· 4 shared A. Choi· 3 shared F. Krammer· 3 shared G. Singh· 3 shared I. Mena· 3 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersImmunology

M. Schotsaert

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in QIV vaccinated mice.

S. Jangra, A. Lamoot, G. Singh, G. Laghlali, Y. Chen, T. Ye, A. Garcia-Sastre, B. G. De Geest, M. Schotsaert

This study evaluates how lipid nanoparticle (LNP) composition and adjuvant combinations affect immune responses and protection in mice vaccinated against influenza.

bioRxiv · Jan 14, 2024 · PreprintMicrobiology

Protocol for primary human lung organoid-derived air-liquid interface in vitro model to study response to SARS-CoV-2

D. C. Castaneda, S. Jangra, M. Yurieva, J. Martinek, M. Callender, M. Coxe, A. Choi, J. G.-B. Diego, T.-C. Wu, F. Marches, D. Chaussabel, A. Garcia-Sastre, M. Schotsaert, A. Williams, K. Palucka

This paper presents a protocol for creating human lung organoid-derived air-liquid interface cultures to study SARS-CoV-2 infection and includes quality control and monitoring methods.

bioRxiv · Sep 10, 2023 · PreprintImmunology

SARS-CoV-2 infection triggers pro-atherogenic inflammatory 1 responses in human coronary vessels

N. Eberhardt, M. G. Noval, R. Kaur, S. Sajja, L. Amadori, D. Das, B. Cilhoroz, O. J. Stewart, D. M. Fernandez, R. Shamailova, A. V. Guillen, S. Jangra, M. Schotsaert, M. Gildea, J. D. Newman, , C. Giannarelli

This study shows SARS-CoV-2 infects macrophages in coronary atherosclerotic lesions, causing inflammation that may increase cardiovascular risk.

bioRxiv · Aug 14, 2023Immunology

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian Hamsters

J. Garcia-Bernalt Diego, G. Singh, S. Jangra, K. Handrejk, M. Laporte, L. A. Chang, S. S. El Zahed, L. Pache, M. W. Chang, P. Warang, S. Aslam, I. Mena, B. T. Webb, C. Benner, A. Garcia-Sastre, M. Schotsaert

This study evaluates hybrid immunity in mRNA-vaccinated hamsters during breakthrough infections, finding enhanced cross-reactive immune responses despite low neutralizing antibody titers.

bioRxiv · May 22, 2023Microbiology

Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia

D. C. Castaneda, S. Jangra, M. Yurieva, J. Martinek, M. Callender, M. Coxe, A. Choi, J. G.-B. Diego, J. Lin, T.-C. Wu, F. Marches, D. Chaussabel, P. Yu, A. Salner, G. Aucello, , K. Palucka

This study examines the spatiotemporal immune response to SARS-CoV-2 in human broncho-alveolar epithelia, finding variant-specific kinetics and spatially organized gene expression patterns.

bioRxiv · Mar 30, 2023Immunology

Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.

T. Kehrer, A. Cupic, C. Ye, S. Yildiz, M. Bouhhadou, N. A. Crossland, E. Barrall, P. Cohen, A. Tseng, T. Cagatay, R. Rathnasinghe, D. Flores, S. Jangra, F. Alam, N. Mena, , L. Miorin

This study shows SARS-CoV-2 ORF6 disrupts nucleo-cytoplasmic trafficking, inhibits IFN signaling, and modulates viral protein expression, with variant polymorphisms affecting its function.

bioRxiv · Oct 18, 2022Microbiology

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters

L. Miorin, C. E. Mire, S. Ranjbar, A. J. Hume, J. Huang, N. A. Crossland, K. M. White, M. Laporte, T. Kehrer, V. Haridas, E. Moreno, A. Nambu, S. Jangra, A. Cupic, M. Dejosez, , A. E. Goldfeld

The paper shows that nitazoxanide inhibits SARS-CoV-2 replication and pathogenesis in human and hamster models, and synergizes with remdesivir against multiple variants.

bioRxiv · Feb 8, 2022 · PreprintImmunology

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

J. A. Duty, T. A. Kraus, H. Zhou, Y. Zhang, N. Shaabani, S. Yildiz, N. Du, A. Singh, L. Miorin, D. Li, K. Stegman, S. I. Ophir, X. Cao, K. Atanasoff, R. Lim, , R. Allen

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

bioRxiv · Jan 19, 2022 · PreprintMicrobiology

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

W. Sun, Y. Liu, F. Amanat, I. Gonzalez-Dominguez, S. McCroskery, S. Slamanig, L. Coughlan, V. Rosado, N. Lemus, S. Jangra, R. Rathnasinghe, M. Schotsaert, J. Martinez, K. Sano, I. Mena, , P. Palese

This study develops a Newcastle disease virus-based vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein, showing strong immune responses and cross-neutralization against variants in mice and hamsters.

bioRxiv · Jul 6, 2021 · PreprintImmunology

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

R. Rathnasinghe, M. Salvatore, H. Zheng, S. Jangra, T. Kehrer, I. Mena, M. Schotsaert, T. Muster, P. Palese, A. Garcia-Sastre

This study shows that a live attenuated influenza virus vaccine lacking NS1 provides broad protection against respiratory viruses including SARS-CoV-2 by inducing both innate and adaptive immune responses.

bioRxiv · Apr 28, 2021Microbiology

A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine

S. Jangra, J. J. Landers, R. Rathnasinghe, J. J. O'Konek, K. W. Janczak, M. Cascalho, A. A. Kennedy, A. W. Tai, J. R. Baker, M. Schotsaert, P. T. Wong

This study develops a combination adjuvant that enhances antiviral immune responses to a SARS-CoV-2 protein vaccine, showing improved TH1 responses and neutralizing antibodies against variants in mice.

bioRxiv · Feb 18, 2021Immunology

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine

S. Jangra, J. De Vrieze, A. Choi, R. Rathnasinghe, G. Laghlali, A. Uvyn, S. Van Herck, L. Nuhn, K. Deswarte, Z. Zhong, N. Sanders, S. Lienenklaus, S. David, S. Strohmeier, F. Amanat, , M. Schotsaert

This paper demonstrates that a novel TLR7/8 agonist adjuvant enables single-shot protection against SARS-CoV-2 and influenza in mice using recombinant spike protein and inactivated vaccines.

bioRxiv · Oct 23, 2020Microbiology